Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|12|1645-1653

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.12, 2015-04, pp. : 1645-1653

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zebrafish Model in Drug Safety Assessment

By  

Current Pharmaceutical Design, Vol. 20, Iss. 34, 2014-10 ,pp. : 5416-5429

Bentham Science Publishers

Access to resources Recommend Favorite

Zebrafish: A Complete Animal Model for In Vivo Drug Discovery and Development

By  

Current Drug Metabolism, Vol. 10, Iss. 2, 2009-02 ,pp. : 116-124

Bentham Science Publishers

Access to resources Recommend Favorite

Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs

By  

Current Drug Delivery, Vol. 14, Iss. 4, 2017-07 ,pp. : 516-520

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study

By Mukherjee J.   Yang Z.-Y.  

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 111-114

Elsevier

Access to resources Recommend Favorite

Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

By  

Current Cancer Drug Targets, Vol. 16, Iss. 4, 2016-04 ,pp. : 288-304

Bentham Science Publishers

Access to resources Recommend Favorite